CTOs on the Move

Pernix Therapeutics Holdings, Inc.

www.pernixtx.com

 
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: TREXIMET®, SILENOR®, a non-narcotic product indicated for the treatment of insomnia characterized by difficulties with sleep maintenance, KHEDEZLA™, as well as CEDAX®, an antibiotic for middle ear infections. The Company promotes its branded products to physicians through its Pernix sales force and distributes its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. Founded in 1996, the Company is based in Morristown, New Jersey.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pernixtx.com
  • 10 N Park Pl Ste 201
    Morristown, NJ USA 07960
  • Phone: 800.793.2145

Executives

Name Title Contact Details

Similar Companies

DaVita Rx

DaVita RxⓇ is the first and largest full-service pharmacy created specifically for the unique needs of kidney patients, and has expanded to other complex conditions as well. We make it easier for patients to get their medications and follow their drug regimens. We give providers a whole new way to improve patient care.

Presbyterian Medical Services

Presbyterian Medical Services (PMS) is the successor to the United Presbyterian Churchs Medical Mission work in the Southwest which began in 1901. In 1969, an independent PMS was formed as a New Mexico non-profit corporation to ensure continuation of...

RxElite (Main)

RxElite (Main) is a Meridian, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope

Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C

Idorsia

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe`s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.